(415) 353-2421 (appts)
(415) 353-2545 (fax)

Box 0324, UCSF; San Francisco, CA 94143-0324

additional websites:

UCSF Physician Referral Directory

Brandeis University (Magna cum Laude), BA, 1974, Biology
University of California, Berkeley, MA, 1976, Biochemistry
University of California, Los Angeles, MD, 1980, Medicine

Kaplan LD, Volberding P, Abrams D. Treatment of Kaposi's sarcoma in acquired immunodeficiency syndrome with an alternating vincristine vinblastine regimen. Ca Treat Rep 1986 70(9): 1121 2.

Kaplan LD, Wolfe PR, Volberding PA, Feorino P, Levy JA, Abrams D, Kiprov D, Wong, Kaufman L, Gottlieb M. Lack of response to suramin by patients with AIDS and AlDS related complex. Am J Med 1987; 82:615 620.

Kaplan LD, Hopewell PC, Jaffe H, Goodman PC, Bottles K, Volberding PA. Kaposi's sarcoma involving the lung in patients with the acquired immunodeficiency syndrome. J Acquired Immun Def Syndr 1988; 1 :23 30.

Kaplan LD, Abrams Dl, Feigal E, McGrath MS, Ziegler J, Volberding PA. AIDS associated nonÂHodgkin's Iymphoma in San Francisco. JAMA 1989; 261:719 724.

Kaplan LD, Kahn J, Jacobson M, Bottles K, Cello J. Primary Non Hodgkin's Iymphoma of extrahepatic bile ducts in Acquired Immunodeficiency Syndrome. Ann Intern Med 1989;110: 161-Â162.

Kaplan LD. AlDS associated non Hodgkin's Iymphoma. Current Opinion in Oncology 1989; 1:62 67.

Kaplan LD, Kahn J, Crowe S, Northfelt D, Neville P, Grossberg H, Abrams 1, Tracey J, Mills J, Volberding P. Clinical and virologic effects of recombinant human granulocyte macrophage colony stimulating factor (rGM CSF) in patients receiving chemotherapy for HIV associated nonÂ-Hodgkin's Iymphoma: results of a randomized trial. J Clin Oncol 1991;9:929 940.

Kahn J, Kaplan LD, Bredesen D et al. The safety and pharmacokinetics of GLQ223 in subjects with acquired immunodeficiency syndrome (AIDS) and AIDS related complex: A phase 1 study. AIDS (1990) 4:1197 1204.

Levine AM, Wernz JC, Kaplan LD, Rodman N, Cohen P, Metroka C, et. al. Low dose chemotherapy with central nervous system prophylaxis and azidothymidine maintenance in AIDS related Iymphoma: A prospective multi institutional trial. JAMA 1991; 226:84 88.

McGrath MS, Shiramizu B, Meeker TC, Kaplan LD, Herndier B. AIDS associated polyclonal Iymphoma: Identification of a new HlV associated disease process. J Clin Oncol 1992; 10:383Â389.

Shiramizu B, Herndier, Meeker T, Kaplan LD, McGrath M. Molecular and immunophenotypic characterization of AlDS associated Epstein Barr virus negative polyclonal Iymphoma. J of Oncol 1992; 10:383.

Kaplan LD, Shiramizu B, Herndier B, Kahn J, Meeker TC, Ng V, Volberding PA, McGrath M. Influence of molecular characteristics on clinical outcome in HIV associated non Hodgkin's Iymphoma: Identification of subgroup with favorable clinical outcome. Blood. 1995: 85:1727-1735.

Meeker TC, Kaplan LD, Herndier B, Grimaldi JC, Baumgartner J, Rachlin J, Feigal E, Rosenblum M, and McGrath M. Evidence for molecular subtypes of HIV associated Iymphoma: Division into peripheral monoclonal Iymphoma, peripheral polyclonal Iymphoma, and central nervous system Iymphoma. AIDS 1991;5: 669 674.

Hendier BG, Kaplan LD, mcGrath MS. Pathogensis of AIDS Lymphoma. AIDS 1994,8:1025-1049.

Northfelt DW, Martin FJ, Working P, Volberding, PA, Russell J, Newman M, and Kaplan LD. Pharmacokinetics, tumor localization, and safety of PEG-liposomal doxorubicin in patients with AIDS-related Kaposi's sarcoma. J Clin Pharmacol 1996; 36: 55-63

Kaplan LD, Straus DJ, Testa MA, et al. Low-dose vs Standard-dose mBACOD Chemotherapy for HIV-associated non-Hodgkin's Lymphoma. N Engl J Med, 1997:336:1641-1648

Straus, DJ, Huang, J, Testa, MA, Levine, AM, and Kaplan, LD. Prognostic factors in the treatment of HIV-associated non-Hodgkin lymphoma. Analysis of AIDS Malignancy Clinical Group (ACTG) Protocol 142: low-dose vs. standard-dose m-BACOD + GM-CSF. J Clin Oncol,1998,16,3601-06.

Ratner L, Lee J, Tang S, Redden D, Hamzeh F, Herndier B, Scadden D, Kaplan LD, Ambinder R, Levine A, Harrington W, Grochow L, Flexner C, Tan B, and Straus D, Chemotherapy for HIV-associated non-Hodgkin's Lymphoma in Combination with Highly Active Antiretroviral Therapy. 2001; J Clin Oncol 2001 19:2171-2178

Steven A. Miles, Bruce Dezube, Wayne Saville, Jeannette Lee, Lawrence Kaplan, Jerome Groopman, David Scadden, Timothy Cooley, Anthony Cheung, Alvin Friedman-Kien and the AIDS Malignancy Consortium. Antitumor Activity of 9-cis retinoic acid in Kaposi's Sarcoma. AIDS. 2002 Feb 15; 16(3):421-9

Kaplan LD Functional Imaging in the management of Lymphoma: Editorial. Am J Med. 2002 Mar; 112(4): 320-1

Gates A., Kaplan LD. Biology and Management of AIDS-Associated non-Hodgkin's Lymphoma Hematology/Oncology Clinics of North America 2003; 17, 821-841 AIDS malignancies in the era of highly active an tiretroviral therapy. Oncology .2002 May; 16(5): 657-65; discussion 665, 668-70.

Kaplan LD., Afridi N. A., Holmvang G., Zukerberg L. R. Case Records of the Massachusetts General Hospital, N Engl J Med. 2003; 349:1369-137.

Kaplan LD, Lee JY, Ambinder RF, Sparano JA, Cesarman E, Chadburn A, Levine AM, Scadden DT. Rituximab does not Improve Clinical Outcome in a Randomized Phase 3 Trial of CHOP with or without Rituximab in Patients with HIV-Associated Non-Hodgkin's Lymphoma: AIDS-Malignancies Consortium Trial 010. Blood, 2005; 106:1538-1543

Navarro W and Kaplan LD. HIV-Associated Lymphoproliferative Disease. Blood, 2006; 107: 13-20

8/22/06